Cardiol Therapeutics Inc.

A clinical-stage biotechnology company focused on developing innovative therapies for inflammatory heart disease.

Recent News

  • Cardiol Therapeutics Announces Topline Results from Phase I Single and Multiple Ascending Dose Clinical Trial of CardiolRx(TM)

    Oakville, Ontario--(Newsfile Corp. - April 12, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease (CVD), today announced topline results from a Phase I single and multiple ascending dose clinical trial of CardiolRx™, a pharmaceutically produced oral cannabidiol formulation being developed for the treatment of acute and chronic inflammation associated with heart disease."As our study represents one of...

    2021-04-12 7:40 AM ET
  • Cardiol Therapeutics Announces Filing of 2020 Year-End Financial Statements and MD&A

    Oakville, Ontario--(Newsfile Corp. - April 1, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, today filed its audited Financial Statements and Management's Discussion and Analysis for the year ended December 31, 2020. Both are available under the Company's profile on SEDAR at www.sedar.com and on the Company's website at www.cardiolrx.com.David Elsley, President and Chief Executive Offi

    2021-04-01 8:43 AM ET
  • Cardiol Therapeutics Appoints Dr. Andrew Hamer as New Chief Medical Officer

    Oakville, Ontario--(Newsfile Corp. - March 30, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, today announced that Dr. Andrew Hamer has joined the Company as Chief Medical Officer (CMO), effective immediately. Dr. Hamer will lead the research and development of the Company's clinical-stage products and will also guide the development of additional novel therapeutics in the Company's...

    2021-03-30 7:03 AM ET
  • Cardiol Therapeutics stellt Antrag auf Nasdaq-Uplisting und erzielt Erlöse von mehr als 10 Mio. USD aus der Ausübung von Optionsscheinen und Optionen

    Oakville, Ontario--(Newsfile Corp. - Dienstag, 2. März 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) ("Cardiol" oder das "Unternehmen"), ein Biotechnologieunternehmen im klinischen Stadium mit Fokus auf der Entwicklung innovativer entzündungshemmender Therapien zur Behandlung von Herz-Kreislauf-Erkrankungen gab heute bekannt, einen Antrag auf ein Uplisting seiner Stammaktien auf The Nasdaq Capital Market® ("Nasdaq") gestellt und einen Erlös von über 10 Mio. USD aus der Ausübung von Optionsscheinen und Aktienoptionen erzielt zu haben."Nasdaq ist die führende Börse für Biotechnologieunternehmen...

    2021-03-02 11:17 AM ET
  • Cardiol Therapeutics Submits Application for Uplisting to the Nasdaq and Raises Proceeds of Over $10 Million from Exercise of Warrants and Options

    Oakville, Ontario--(Newsfile Corp. - March 2, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) (FSE: CT9) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, announced today that it has submitted an application to uplist the Company's common shares on The Nasdaq Capital Market® (the "Nasdaq") and that it has received proceeds of over $10 million from the exercise of warrants and stock options."The Nasdaq is the premier...

    2021-03-02 8:27 AM ET
  • Cardiol Therapeutics Announces Formation of Data Safety Monitoring and Clinical Endpoint Committees for Phase II/III Outcomes Trial in High-Risk Patients Hospitalized with COVID-19

    Oakville, Ontario--(Newsfile Corp. - January 21, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease, today announced the formation of the Data Safety Monitoring Committee ("DSMC") and the Clinical Endpoint Committee ("CEC") for the Company's Phase II/III trial in high-risk patients hospitalized with COVID-19 at clinical centers throughout the United States.The DSMC comprises independent experts...

    2021-01-21 8:27 AM ET
  • Cardiol Therapeutics to Participate in Upcoming Virtual Investor Conferences

    Oakville, Ontario--(Newsfile Corp. - January 7, 2021) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative therapies for inflammatory heart disease, announced today that David Elsley, President and CEO of Cardiol, will participate in the following upcoming virtual investor conferences: 10th Annual LifeSci Partners Corporate Access Event - January 6-8 and 11-14, 2021. Mr. Elsley will present, participate in a panel discussion "Developing Drugs for Cardiovascular Indications", and hold...

    2021-01-07 8:27 AM ET
  • Cardiol Therapeutics Announces Completion of Phase I Clinical Study of CardiolRx(TM)

    Oakville, Ontario--(Newsfile Corp. - December 22, 2020) - Cardiol Therapeutics Inc. (TSX: CRDL) (OTCQX: CRTPF) ("Cardiol" or the "Company"), a clinical-stage biotechnology company focused on developing innovative therapies for inflammatory heart disease, is pleased to announce completion of the Company's Health Canada approved Phase I clinical study of CardiolRx™. CardiolRx is an ultra-pure, extra strength cannabidiol oral formulation that is pharmaceutically produced, manufactured under cGMP, and THC-free (<10 ppm).Cardiol's Phase I double-blind, placebo-controlled, randomized study was designed to assess safety,...

    2020-12-22 8:27 AM ET